Co-expression of PKCζ and ALDH1A3 Is Associated With Poor Chemotherapeutic Responses in Basal-like Breast Cancer
Authors:
Open Access
- 1 March 2026
- journal article
- Published by International Institute of Anticancer Research in Cancer Genomics & Proteomics
- Vol. 23 (2) , 322-341
Abstract
The association between the expression of protein kinase C zeta (PKCζ) and chemotherapeutic responses among different subtypes of breast cancer has yet to be fully elucidated. The present study aimed to investigate the association between PKCζ expression and disease-specific survival (DSS) rates, with a particular focus on the influence of chemotherapy and cancer stem cell (CSC)-associated ALDH1A3 expression. Clinical and gene expression data from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) dataset (n=2,509) were analyzed using Kaplan-Meier and Cox proportional hazards models. The findings were validated using The Cancer Genome Atlas (TCGA) Pan-Cancer Atlas dataset (n=1,084). In the METABRIC dataset, high PKCζ expression (PKCζ high) was associated with poor DSS rates in patients with the normal-like, claudin-low and basal-like subtypes treated with chemotherapy. Consistent results were obtained in TCGA dataset, where PKCζ high expression in basal-like breast cancer predicted poor prognosis, especially among patients treated with cyclophosphamide, an alkylating agent. Combined analysis further revealed that patients with high expression of both PKCζ and ALDH1A3 (PKCζ high/ALDH1A3 high) basal-like tumors treated with cyclophosphamide, doxorubicin, or fluorouracil had the worst DSS rates compared with other groups. In addition, PKCζ high/ALDH1A3 high basal-like tumors treated with anthracycline- or taxane-based regimens also exhibited poorer prognoses compared with other groups. PKCζ contributes to chemotherapeutic resistance, especially in patients with ALDH1A3-positive basal-like breast cancer, possibly through the regulation of CSC survival and proliferation. Moreover, PKCζ, either alone or in combination with ALDH1A3 expression, may serve as a prognostic biomarker for predicting the therapeutic efficacy of chemotherapy in basal-like breast cancer.Keywords
This publication has 75 references indexed in Scilit:
- Stem cells, cancer, and cancer stem cellsNature, 2001
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001
- The atypical protein kinase CsEMBO Reports, 2000
- Molecular portraits of human breast tumoursNature, 2000
- The extended protein kinase C superfamilyBiochemical Journal, 1998
- PKC zeta is a molecular switch in signal transduction of TNF‐alpha, bifunctionally regulated by ceramide and arachidonic acid.The EMBO Journal, 1995
- Activation of protein kinase C family members by the novel polyphosphoinositides PtdIns-3,4-P2 and PtdIns-3,4,5-P3.Journal of Biological Chemistry, 1994
- Protein kinase C zeta isoform is critical for kappa B-dependent promoter activation by sphingomyelinase.Journal of Biological Chemistry, 1994
- A new member of the third class in the protein kinase C family, PKC lambda, expressed dominantly in an undifferentiated mouse embryonal carcinoma cell line and also in many tissues and cells.Journal of Biological Chemistry, 1994
- Activation of the zeta isozyme of protein kinase C by phosphatidylinositol 3,4,5-trisphosphate.Journal of Biological Chemistry, 1993